Nifty
Sensex
:
:
11844.10
39434.72
187.05 (1.60%)
623.33 (1.61%)

Pharmaceuticals & Drugs

Rating :
50/99

BSE: 500257 | NSE: LUPIN

763.30
13.35 (1.78%)
24-May-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  747.00
  •  766.15
  •  747.00
  •  749.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  762430
  •  5819.63
  •  986.10
  •  719.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 33,902.39
  • 55.89
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 39,637.16
  • 0.67%
  • 2.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.97%
  • 1.25%
  • 11.45%
  • FII
  • DII
  • Others
  • 0.43%
  • 11.65%
  • 28.25%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.12
  • 6.97
  • 3.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.59
  • 0.95
  • -3.11

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.87
  • -33.01
  • -52.11

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.66
  • 26.58
  • 23.01

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.68
  • 5.51
  • 3.78

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.19
  • 16.56
  • 14.15

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
4,406.32
4,033.83
9.23%
4,504.87
3,975.62
13.31%
3,951.06
3,951.96
-0.02%
3,855.93
3,869.58
-0.35%
Expenses
3,534.03
3,325.08
6.28%
3,752.33
3,287.28
14.15%
3,401.42
3,098.91
9.76%
3,328.96
3,101.21
7.34%
EBITDA
872.29
708.75
23.07%
752.54
688.34
9.33%
549.64
853.05
-35.57%
526.97
768.37
-31.42%
EBIDTM
19.80%
17.57%
16.70%
17.31%
13.91%
21.59%
13.67%
19.86%
Other Income
86.50
144.92
-40.31%
43.42
28.42
52.78%
230.68
74.04
211.56%
184.20
31.97
476.17%
Interest
85.52
58.53
46.11%
79.77
54.00
47.72%
73.82
47.92
54.05%
68.72
43.90
56.54%
Depreciation
280.78
272.83
2.91%
279.76
280.35
-0.21%
265.49
272.18
-2.46%
258.98
260.51
-0.59%
PBT
594.73
-942.04
-
94.21
382.41
-75.36%
441.01
606.99
-27.34%
383.47
495.93
-22.68%
Tax
299.84
-163.18
-
247.80
160.77
54.13%
172.91
154.06
12.24%
181.14
136.81
32.40%
PAT
294.89
-778.86
-
-153.59
221.64
-
268.10
452.93
-40.81%
202.33
359.12
-43.66%
PATM
6.69%
-19.31%
-3.41%
5.58%
6.79%
11.46%
5.25%
9.28%
EPS
6.40
-17.33
-
-3.35
4.91
-
5.88
10.07
-41.61%
4.48
7.93
-43.51%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
16,718.18
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
3,866.64
Net Sales Growth
5.60%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
25.97%
 
Cost Of Goods Sold
5,845.79
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
1,604.09
Gross Profit
10,872.39
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
2,262.55
GP Margin
65.03%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
58.51%
Total Expenditure
14,016.74
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
3,127.36
Power & Fuel Cost
-
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
139.11
% Of Sales
-
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
3.60%
Employee Cost
-
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
474.16
% Of Sales
-
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
12.26%
Manufacturing Exp.
-
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
261.34
% Of Sales
-
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
6.76%
General & Admin Exp.
-
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
192.75
% Of Sales
-
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
4.98%
Selling & Distn. Exp.
-
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
354.48
% Of Sales
-
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
9.17%
Miscellaneous Exp.
-
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
121.51
354.48
% Of Sales
-
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
2.62%
EBITDA
2,701.44
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
739.28
EBITDA Margin
16.16%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
19.12%
Other Income
544.80
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
4.61
Interest
307.83
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
49.86
Depreciation
1,085.01
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
87.99
PBT
1,513.42
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Tax
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
98.30
Tax Rate
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
16.22%
PAT
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
504.88
PAT before Minority Interest
602.80
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
507.74
Minority Interest
-8.93
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
-2.86
PAT Margin
3.66%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
13.06%
PAT Growth
140.05%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
36.37%
 
Unadjusted EPS
13.41
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84
60.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
1,424.82
Share Capital
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
82.82
Total Reserves
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
1,341.93
Non-Current Liabilities
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
1,339.71
Secured Loans
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
756.92
Unsecured Loans
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
466.35
Long Term Provisions
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
0.00
Current Liabilities
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
1,216.19
Trade Payables
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
710.25
Other Current Liabilities
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
323.23
Short Term Borrowings
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
0.00
Short Term Provisions
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
182.71
Total Liabilities
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97
Net Block
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
1,518.57
Gross Block
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
2,137.40
Accumulated Depreciation
2,459.58
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
618.83
Non Current Assets
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
1,764.10
Capital Work in Progress
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
222.62
Non Current Investment
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
21.56
Long Term Loans & Adv.
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
0.00
Other Non Current Assets
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
0.00
Current Assets
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
2,230.87
Current Investments
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
0.00
Inventories
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
957.16
Sundry Debtors
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
917.97
Cash & Bank
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
77.77
Other Current Assets
1,711.95
533.43
479.44
240.07
532.99
572.33
427.17
628.48
475.86
277.97
Short Term Loans & Adv.
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
277.97
Net Current Assets
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
1,014.68
Total Assets
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
469.54
PBT
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Adjustment
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
144.21
Changes in Working Capital
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
-173.89
Cash after chg. in Working capital
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
576.36
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
-106.82
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,407.27
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
-509.62
Net Fixed Assets
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
-223.23
Net Investments
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
-181.38
Others
-1,564.03
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
-105.01
Cash from Financing Activity
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
-167.15
Net Cash Inflow / Outflow
-1,148.18
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
-207.23
Opening Cash & Equivalents
2,799.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
270.66
Closing Cash & Equivalent
1,651.29
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99
68.08

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
34.41
ROA
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
13.83%
ROE
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
37.55%
ROCE
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
25.57%
Fixed Asset Turnover
1.20
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
2.05
Receivable days
109.70
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
77.48
Inventory Days
84.35
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
81.42
Payable days
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
62.70
Cash Conversion Cycle
125.48
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
96.21
Total Debt/Equity
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
0.86
Interest Cover
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71
13.15

News Update:


  • Lupin launches Budesonide Inhalation Suspension
    22nd May 2019, 14:22 PM

    Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules had annual sales of approximately $385.4 million in the US

    Read More
  • USFDA completes inspection of Lupin's Aurangabad facility
    16th May 2019, 10:15 AM

    The inspection at the Aurangabad facility closed with three observations

    Read More
  • Lupin to review US lawsuit accusing it of price fixing, customer allocation
    15th May 2019, 16:10 PM

    The company has been a key pharmaceutical player in the US and has demonstrated full commitment to compliance with all laws and ethical business practices

    Read More
  • Lupin turns black in Q4
    15th May 2019, 15:26 PM

    Total consolidated income of the company rose 7.52% at Rs 4,492.82 crore for quarter ended March 31, 2019

    Read More
  • Lupin - Quarterly Results
    15th May 2019, 14:54 PM

    Read More
  • Lupin receives EIR from USFDA
    14th May 2019, 10:48 AM

    The inspection was conducted at company’s global pharmacovigilance group DSRM based out of Mumbai between January 14, 2019 and January 18, 2019

    Read More
  • Lupin launches Clobazam Tablets
    10th May 2019, 12:07 PM

    It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older

    Read More
  • Lupin, Aptissen enters into distribution agreement to market Synolis VA in Canada
    9th May 2019, 14:27 PM

    Based on Statistics Canada, Osteoarthritis affects more than 10% of Canadians aged 15 or older

    Read More
  • Lupin gets more time from government to complete project at Indore SEZ
    8th May 2019, 14:23 PM

    The decision to give more time was taken by the Board of Approval in its meeting held on April 22

    Read More
  • Lupin receives tentative USFDA approval for Fosaprepitant for Injection
    7th May 2019, 15:39 PM

    Lupin's Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic version of Merck's Emend for Injection, 150 mg Single-Dose Vial

    Read More
  • Lupin’s arm recalls Morphine Sulfate extended-release tablets in US
    6th May 2019, 10:36 AM

    The recalling is in various strengths due to failed impurities/degradation specifications

    Read More
  • Lupin in alliance with Natco receives USFDA approval for Bosentan Tablets
    2nd May 2019, 09:44 AM

    It is indicated for the treatment of pulmonary arterial hypertension in adults

    Read More
  • USFDA classifies inspection of Lupin's Pithampur facility as OAI
    24th Apr 2019, 14:30 PM

    The company is in the process of sending further updates of its corrective actions to the USFDA and is hopeful of a positive outcome

    Read More
  • Lupin seeks more time from commerce ministry to complete project in Indore SEZ
    20th Apr 2019, 11:33 AM

    The company’s plea for extension of time will be considered by the highest decision making body of SEZs - BoA - in its meeting on April 22

    Read More
  • Lupin gets USFDA’s approval for Fluoxetine Tablets
    16th Apr 2019, 14:24 PM

    The company’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic version of Eli Lilly’s Prozac Tablets, 10 mg and 20 mg

    Read More
  • Lupin launches Testosterone Gel
    12th Apr 2019, 11:20 AM

    The company has launched Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation)

    Read More
  • Lupin gets USFDA’s approval for Testosterone Gel
    11th Apr 2019, 12:23 PM

    The company’s Testosterone Gel, 1.62% is the generic equivalent of AbbVie’s AndroGel, 1.62%

    Read More
  • Lupin launches Fluoxetine Tablets
    10th Apr 2019, 12:50 PM

    It is indicated in the treatment of Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa and panic disorder

    Read More
  • Lupin’s arm recalls over 12,000 cartons of Fayosim tablets from US market
    8th Apr 2019, 10:50 AM

    The reason for the recall is ‘Failed impurities/ degradation specifications

    Read More
  • USFDA concludes inspection at Lupin’s Bioresearch Centre
    3rd Apr 2019, 10:35 AM

    The USFDA has completed inspection without any observations

    Read More
  • Lupin’s Pithampur Unit-3 receives EIR from USFDA
    2nd Apr 2019, 10:38 AM

    The inspection was conducted between October 8, 2018 to October 18, 2018

    Read More
  • Lupin launches Tadalafil Tablets
    1st Apr 2019, 15:13 PM

    Lupin's Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, is the generic equivalent of Eli Lilly and Company's Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg

    Read More
  • Lupin’s arm recalls 3,200 bottles of Testosterone Topical Solution in US
    1st Apr 2019, 10:17 AM

    USFDA has received the repetitive complaints regarding the container indicating faulty pump

    Read More
  • Lupin launches Fluocinonide Ointment
    28th Mar 2019, 16:22 PM

    It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

    Read More
  • Lupin receives USFDA’s approval for Tadalafil Tablets
    27th Mar 2019, 15:25 PM

    Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg had annual sales of approximately $1780 million in the US

    Read More
  • Lupin receives EU GMP certificate for Pune Biotech facility
    27th Mar 2019, 11:14 AM

    This GMP certification further confirms that the company has a robust manufacturing facility that ensures consistent and controlled production as per EU quality standards

    Read More
  • Lupin, YL Biologics receive PMDA approval for Etanercept biosimilar in Japan
    26th Mar 2019, 11:45 AM

    The approval to treat moderate to severe Rheumatoid Arthritis and Juvenile Idiopathic Arthritis was received on March 26, 2019

    Read More
  • Lupin receives USFDA’s approval for Sildenafil Tablets
    25th Mar 2019, 11:57 AM

    Sildenafil Tablets USP had an annual sales of approximately $611 million in the US

    Read More
  • Lupin launches Levothyroxine Sodium Tablets
    22nd Mar 2019, 12:28 PM

    Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc’s Synthroid Tablets

    Read More
  • USFDA classifies Lupin's Somerset facility as ‘Official Action Indicated’
    18th Mar 2019, 10:26 AM

    Official Action Indicated means approvals of pending applications or supplements from this site maybe withheld

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.